Giant NPE sold; the US’s first clean hands patent thicketing challenge; inside AT&T’s portfolio; why Huawei owns the future; and much more
With news, analysis and data from across the IP market, it has been another very busy week on the IAM platform. Here are all the stories we covered
MONDAY 11th February
Deep pockets, a strong commitment to R&D and a world class 5G patent portfolio mean that whatever its current difficulties Huawei is set to be a major player for the long term. Read more here
RPX has agreed a $17.5 million deal to acquire a patent portfolio from Creative subsidiary ZiiLabs in a move that ends the Singapore outfit’s litigation against Nvidia. Read more here
Apple’s courtroom strategy shows that the team monetising a former portfolio of Blackberry patents faces its biggest licensing challenge yet. Read more here
TUESDAY 12th February
An annual survey conducted by China’s National Intellectual Property Administration pegs the licensing rate of Chinese patents at 5.5%. That's not far off estimates of US patent utilisation. Read more here
AT&T is building its presence in the secondary market with a host of companies now seeking out its high-quality patents. Read more here
Former Intellectual Ventures unit teams up with alternative asset business to give large and small innovators a way of attracting finance on blockchain-based initiative. Read more here
WEDNESDAY 13th February
IPBC Global 2019 is shaping up to be the biggest and best of the series so far. Read more here
THURSDAY 14th February
The world’s most valuable startup has moved into the secondary patent market again – this is what it got its hands on. Read more here
With new guidelines set to reshape patent examination, the USPTO director has sent a clear message to the CAFC in a speech that made the case for looking again at subject matter precedent. Read more here
Although female patentees are becoming more common – particularly in areas such as pharma and biotech – the rate of growth is slowing. Read more here
FRIDAY 15th February
An aggressive move by Australia’s largest public IP services group seems designed to thwart the merger of two smaller rivals. But further consolidation in the space still looks likely. Read more here
AbbVie’s Humira strategy is to be scrutinised in the US’s first unclean hands challenge of patent thicketing. Read more here
A giant NPE that owns thousands of former Ericsson and Panasonic patents has been purchased by a New York-based private equity firm. Read more here